References
- Wallace DM, Harris DL. Delay in treating bladder tumours. Lancet 1965; ii: 332–4.
- Mommsen S, Aagaard, Sell A. Presenting symptoms, treatment delay and survival in bladder cancer. Scand J Urol Nephrol 1983; 17: 163–7.
- Bishop MC. The dangers of a long urological waiting list. Br J Urol 1990; 65: 433–40.
- Gulliford MC, Petruckevitch A, Burney PG. Survival with bladder cancer, evaluation of delay in treatment, type of surgeon and modality of treatment. Br Med J 1991; 303: 437–40.
- Wallace DM, Bryan RT, Dunn JA, Begum G, Bathers S. Delay and survival in bladder cancer. BJU Int 2002; 89: 868–78.
- Sanchez-Ortiz RF, Van Arsdalen KN, Wein AJ, Malkowicz SB, Huang WC. A prolonged interval between the diagnosis of muscle invasion and cystec-tomy is associated with worse outcome in bladder carcinoma. J Urol 2001; 165 (Suppl): 259.
- Messing EM, Young TA, Hunt VB, Gilchrist KW, Newton MA, Bram LL, et al. Comparison of bladder cancer outcome in men undergoing hematuria home screening versus those with standard clinical presenta-tions. Urology 1995; 45: 387–97.
- Mandel JS, Church TR, Ederer F, Bond JH. Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood. J Natl Cancer Inst 1999; 91: 434–7.
- Nystrom L, Andersson I, Bjurstam N, Frisell J, Nordens-kjöld B, Rutqvist LE. Long term effects of mammo-graphy screening: updated overview of the Swedish randomised trials. Lancet 2002; 359: 909–19.
- Britton JP. The effectiveness of hematuria clinics. Br J Urol 1993; 71: 247–52.
- Gulliford M, Petruckevitch A, Burney PG. Hematuria clinics, treatment delay and survival with bladder cancer. Br J Urol 1994; 74: 263–4.
- Hasan ST, German K, Derry CD. Same day diagnostic service for new cases of hematuria-a district general hospital experience. Br J Urol 1994; 73: 152–4.
- Mânsson A, Anderson H, Colleen S. Time lag to diagnosis of bladder cancer-influence of psychosocial parameters and level of health-care provision. Scand J Urol Nephrol 1993; 27: 363–9.
- Cuzick J. A Wilcoxon-type test for trend. Stat Med 1985; 4: 87–90.
- Kalbfleisch JD, Prentice RL The statistical analysis of failure time data. New York: Wiley, 1980: 168–9.
- Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1054 patients. J Clin Oncol 2001; 19: 666–75.
- Wijkström H, Norming U, Lagerkvist M, Nilsson B, Näslund I, Wildund P. Evaluation of clinical staging before cystectomy in transitional cell bladder carcinoma: a long-term follow-up of 276 consecutive patients. Br J Urol 1998; 81: 686–91.
- Holmäng S, Hedelin H, Anderström C, Johansson SL. Long-term followup of all patients with muscle invasive (stages T2, T3 and T4) bladder carcinoma in a geo-graphical region. J Urol 1997; 158: 389–92.
- Christensen E, Harvald T, Jendersen M, Aggestrup S, Pettersson G. The impact of delayed diagnosis of lung cancer on the stage at the time of operation. Eur J Cardiothorac Surg 1997; 12: 880–4.
- Ritchie CD, Bevan EA, Collier SJ. Importance of occult haematuria found at screening. Br Med J 1986; 292: 681–3.
- Thompson IM. The evaluation of microscopic hematuria: a population-based study. J Urol 1987; 138: 1189–90.
- Mayfield MP, Whelan P. Bladder tumours detected on screening: results at 7 years. Br J Urol 1998; 82: 825–8.
- Hemstreet GP, Yin S, Ma Z, Bonner RB, Bi W, Rao JY, et al. Biomarker risk assessment and bladder cancer detection in a cohort exposed to benzidine. J Natl Cancer Inst 2001; 93: 427–36.